Inflectra, which is biosimilar to infliximab, can also be used in the therapy of severe sarcoidosis, with clinical symptoms improved and the serum ACE levels reduced after 26 weeks of Inflectra treatment (48). This evidence concerns the gene ACE and sarcoidosis.